ARA-290

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.277

Reference number

10mg

Lyophilized vial

Origin

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the non-hematopoietic, tissue-protective region of erythropoietin (EPO). It was developed by Araim Pharmaceuticals based on the discovery by Brines and Cerami that EPO's cytoprotective effects could be separated from its blood cell-stimulating activity by targeting the innate repair receptor (IRR).

Research Lineage

Brines, Cerami, and colleagues at the Kenneth S. Warren Institute identified the innate repair receptor as a heterodimer of EPOR and betaC receptor distinct from the classical erythropoietic EPO receptor. ARA-290 was designed to selectively activate this tissue-protective receptor without hematopoietic effects. Phase II clinical trials have been conducted for sarcoidosis-associated neuropathy and diabetic neuropathy.

Mechanism of Action

ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and the beta common receptor (CD131). Unlike full-length EPO, it does not stimulate erythropoiesis through the classical homodimeric EPOR. IRR activation triggers anti-apoptotic and anti-inflammatory signaling cascades through JAK2/STAT5 and PI3K/Akt pathways in non-hematopoietic tissues.

Structural Notes

11-amino-acid linear peptide. Derived from the B helix of erythropoietin. Molecular weight: ~1257 Da.